(VIANEWS) – The Market ended the session with ULTIMOVACS (ULTI.OL) rising 14.02% to kr8.05 on Monday while Oslo Børs Benchmark Index_GI rose 1.37% to kr1,390.11.
ULTIMOVACS’s last close was kr7.06, 96.05% under its 52-week high of kr178.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.5.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.94%.
More news about ULTIMOVACS (ULTI.OL).
